CoChat

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP

Open access
Wang, Lijing · 2022 · Drug Design, Development and Therapy

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

Improving type 2 diabetes using incretin analogues is becoming increasingly plausible. Currently, tirzepatide is the most promising listed incretin analogue. Here, I briefly explain the evolution of drugs of this kind, analyze the residue discrepancies between tirzepatide and endogenous incretins, summarize some existing strategies for prolonging half-life, and present suggestions for future research, mainly involving biased functions. This review aims to present some useful information for designing a dual glucagon like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor agonist.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dddt.s358989

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC BY-NC · PubMed Central
Figure 1 The structures of fatty acid side chains of liraglutide and semaglutide.
Figure 1 The structures of fatty acid side chains of liraglutide and semaglutide.CC BY-NC · PubMed Central
Figure 2 The structures of incretins and analogues. Different color indicates the derivation of each residue. Light blue: GLP-1; Yellow: GIP; dark blue: exenatide; Red: tirzepatide.
Figure 2 The structures of incretins and analogues. Different color indicates the derivation of each residue. Light blue: GLP-1; Yellow: GIP; dark blue: exenatide; Red: tirzepatide.CC BY-NC · PubMed Central
Figure 3 The structures of other two GLP-1R/GIPR dual agonist. Residues in green means they are unique in MAR709 while in orange are unique in CY-5.
Figure 3 The structures of other two GLP-1R/GIPR dual agonist. Residues in green means they are unique in MAR709 while in orange are unique in CY-5.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 60

Metadata

Authors
Wang, L.
Affiliations
China Pharmaceutical University (CN)
Corresponding author
Wang, Lijing
Venue
Drug Design, Development and Therapy
Published
2022-05
Volume
Volume 16
Pages
1547-1559
ISSN
1177-8881 (ISSN-L)
OpenAlex
W4281388633
Cited by
56
References
67
Citations by year
2026: 12 · 2025: 17 · 2024: 15 · 2023: 8 · 2022: 4
FWCI
1.57
Type
journal article
Language
en
Open access
Locations
  • Drug Design Development and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords
tirzepatide, GIP/GLP-1 receptor agonist, GLP-1 receptor, GIP receptor, incretin analogues, type 2 diabetes, biased agonism, drug half-life extension, drug design
MeSH terms
Tirzepatide, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Receptors, Gastrointestinal Hormone, Receptors, G-Protein-Coupled, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.